Costa G, D'Errigo P, Rosato S, et al. - Researchers sought to compare clinical results of balloon‐expandable (BE) and self‐expanding (SE) transcatheter aortic valves (TAVs) up to 5 years. Participants were 1,440 patients registered in the multicenter OBSERVANT study and receiving transfemoral transcatheter aortic valve implantation (TF‐TAVI) with either supra‐annular SE (n = 830, 57.6%) and intra‐annular BE (n = 610, 42.4%) valves. Taking into account the intrinsic limitations of the OBSERVANT study, it was identified that a higher all‐cause mortality was experienced by patients receiving TF‐TAVI with a supra‐annular SE valve vs those receiving an intra‐annular BE valve at 5 years. Beyond 3 years, experts noted a late catch up phenomenon of patients undergoing the BE valve. Seemingly, there is a crucial role of post‐procedural moderate/severe paravalvular regurgitation in ascertaining this finding. To assess the advantage of each specific TAV type, there is a requirement for comparative studies of new generation devices with longer follow‐up.